Back to mobile site

More on QNRX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.0 Score)

Upcoming Events

- Earnings (11/7/25 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Quoin Pharmaceuticals Ltd (NQ:QNRX)
Delayed: 4.23 -0.22 (4.94%)
Prev. Close $4.45  
Open$4.45 
52 Wk High$ 
52 Wk Low$ 
Day High$4.49 
Day Low$4.06 
P/E N/A  
EPS$ 
Volume26,111 

Friends, Peers and Foes (?): 2EB0 (more...)

Jul 9, 2026 08:30 AM Quoin gets FDA clearance for Phase 2 trial of QRX003 in rare skin disease
Jul 9, 2026 08:30 AM Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Jul 6, 2026 05:21 PM Form PRE 14A Quoin Pharmaceuticals, For: Aug 20
Jun 30, 2026 08:31 AM Quoin Pharmaceuticals receives U.S. patent allowance for Netherton drug
Jun 30, 2026 08:30 AM Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
Jun 23, 2026 04:16 PM Form 8-K Quoin Pharmaceuticals, For: Jun 23
Jun 23, 2026 08:31 AM FDA conditionally approves QYLEKI as brand name for Quoin drug
Jun 23, 2026 08:30 AM Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Jun 18, 2026 08:31 AM Quoin Pharma forms Japan subsidiary to advance QRX003 commercialization
Jun 18, 2026 08:30 AM Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
View All Articles

Entities mentioned with QNRX

View All Entities